Cipla
May 28, 2012 at 14:34 | Source: Moneycontrol.com
May 16, 2012 at 12:01 | Source: Moneycontrol.com
May 16, 2012 at 08:36 | Source: Moneycontrol.com
May 16, 2012 at 08:28 | Source: CNBC-TV18
May 10, 2012 at 17:35 | Source: CNBC-TV18
News across the web »
May 29, 2012 at 06:41 | Source: DNA India
May 28, 2012 at 18:27 | Source: Business Standard
May 22, 2012 at 10:02 | Source: DNA India
May 22, 2012 at 10:02 | Source: DNA India
May 22, 2012 at 10:02 | Source: DNA India
Interact & exchange stock tips & market info »
Related News »
Cipla Limited - SWOT Analysis company profile is the essential source for top-level company data and information. Cipla Limited - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary ...
May 17, 2012 at 13:00 | Source: Transworld News
Cipla 's shocking 75% price cut of three cancer drugs on Thursday is unlikely to have a major impact on the pharma major's earnings, analysts say. Cipla cut price of its kidney cancer drug Sorafenib, which is sold under brand name Nexavar by ...
May 16, 2012 at 10:23 | Source: MoneyControl.com
Technical House KRChoksey has suggested buy call for SBI. The stock is good for long term. SBI is pioneer in Indian banking Public sector. The stock has touched 52-week high and low of Rs 2657 and 1571 respectively. SBI is trading currently with a P/E ...
May 16, 2012 at 17:19 | Source: Top News India
The Financial Mail asked if Ciplamed's cautionary on 9 May means the company might be delisted. If speculation is correct, the group could be taken over by its international partner, Cipla India. The cautionary only mentioned that the Ciplamed was "engaged ...
May 25, 2012 at 07:50 | Source: 4-traders (press release)
MUMBAI (Reuters) - Drugmaker Cipla, long a thorn in the side of big pharma, is looking at cutting the prices of more cancer drugs after it slashed the prices of three treatments last week by as much as 75 percent. "Our agents and partners in Africa and ...
May 17, 2012 at 04:31 | Source: in.news.yahoo.com
For 4QFY2012, Cipla reported better-than-expected results on the top-line front, while the bottom line came just in-line with expectations. However, the disappointment came mainly on the back of OPM, which came in at 19.1% vs. our expectations ...
May 16, 2012 at 04:40 | Source: equitybulls.com
The Supreme Court of Appeal (SCA) last month ruled in favour of pharmaceuticals giant Adcock Ingram over a trademark dispute with competitor Cipla Medpro. The companies locked horns over their registered trademarks for the generic of Lisinopril ...
May 24, 2012 at 22:17 | Source: Engineering News
BANGALORE— Cipla Ltd., one of India's largest generic drug manufacturers, said it is cutting prices on its cancer medicines by up to 75%, a move likely to further complicate efforts by big Western pharmaceutical companies seeking to develop ...
May 4, 2012 at 12:25 | Source: Wall Street Journal
Bayer says CIPLA’s new price "will render Natco’s price unreasonable and defeat the purpose of compulsory licensing," according to the newspaper. As that shows, there's been an interesting twist in this story. Cipla, another Indian ...
May 24, 2012 at 02:57 | Source: Tech Dirt
Cipla Ltd reported a net profit of Rs 291.74 crore for the quarter ended March 31, 2012, compared to Rs 214 crore for the quarter ended March 31, 2011. According to an ET Now poll, the pharma major was expected to report a 34% YoY increase in its net ...
May 11, 2012 at 08:56 | Source: 4-traders (press release)